Common Alpha-1 Blockers, Indications, and Side Effects
The five commonly used alpha-1 blockers for lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) are alfuzosin, doxazosin, silodosin, tamsulosin, and terazosin—all demonstrating comparable efficacy with 4-7 point IPSS improvements, but differing significantly in their cardiovascular and ejaculatory side effect profiles. 1
Primary Indication
Alpha-1 blockers are first-line medical therapy for bothersome, moderate to severe LUTS/BPH, regardless of prostate size 1. They work by blocking alpha-1 adrenergic receptors in the prostate and bladder neck, reducing smooth muscle tone and improving urinary flow 2.
The Five Common Alpha-1 Blockers
Efficacy Profile
All five agents show equivalent clinical efficacy for symptom improvement:
- IPSS reduction: 4-7 points (vs. placebo 2-4 points) 1
- Sustained benefit over time with no evidence of tolerance or tachyphylaxis after 6-12 months 2
- Symptom improvement typically occurs within 4 weeks for alpha blockers 1
Key Differentiating Factor: Side Effect Profiles
The choice between agents should be based on patient age, comorbidities, and tolerance for specific adverse events 1, particularly:
Cardiovascular Effects
- Tamsulosin (0.4 mg): Lowest blood pressure impact, minimal orthostatic hypotension, does not reduce elevated blood pressure in normotensive patients 3
- Alfuzosin: More pronounced blood pressure effects, especially in elderly patients 2
- Doxazosin and Terazosin: Effective antihypertensives, greater orthostatic hypotension risk, require dose titration 2, 4
- Silodosin: Cardiovascular profile similar to tamsulosin 5
Ejaculatory Dysfunction
- Silodosin and Tamsulosin: Higher rates of ejaculatory dysfunction due to alpha-1A selectivity 1
- Alfuzosin, Doxazosin, Terazosin: Lower ejaculatory dysfunction rates 1
Common Side Effects
Most Frequent Adverse Events (10-20% of patients) 4:
- Dizziness
- Asthenia (weakness/fatigue)
- Postural/orthostatic hypotension
- Headache
- Drowsiness
- Syncope (particularly with first dose)
Less Common but Important:
- Ejaculatory dysfunction (especially silodosin/tamsulosin)
- Palpitations
- Urinary incontinence
- Priapism (rare)
- Weight gain (1-2 kg, possibly related to secondary hyperaldosteronism) 4
Critical Ophthalmologic Complication:
Intraoperative Floppy Iris Syndrome (IFIS) associated with tamsulosin 5, 1.
Before initiating any alpha blocker, inquire about planned cataract surgery. If surgery is scheduled, delay medication initiation until after the procedure and inform the ophthalmologist of IFIS risk 1.
Practical Prescribing Considerations
First-Dose Phenomenon
The "first-dose effect" (orthostatic hypotension with intense faintness/syncope) is minimized by 4:
- Starting with low doses
- Beginning treatment at bedtime
- Avoiding volume depletion
- Gradual dose titration (for doxazosin/terazosin)
Contraindications 6:
- Cardiac failure
- Renal failure
- History of cerebrovascular events
- Tendency toward hypotension
- Concurrent use of other blood pressure-lowering medications (relative contraindication—requires monitoring)
Clinical Selectivity Advantage
Tamsulosin at 0.4 mg once daily after breakfast represents the most "uroselective" option with high efficacy and low cardiovascular risk, requiring no dose titration 3. This makes it particularly suitable for normotensive patients or those at risk for orthostatic hypotension.
Monitoring and Follow-Up
First follow-up visit should occur at 4 weeks for alpha blockers 1. Assess:
- Adverse medication effects (particularly cardiovascular and ejaculatory)
- IPSS and quality of life scores
- Uroflowmetry/post-void residual when available
Discontinuation rates due to adverse effects occur in approximately 5-10% of patients 4, primarily due to dizziness, asthenia, and orthostatic symptoms.